These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26703951)

  • 1. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.
    Perez-Nieves M; Kabul S; Desai U; Ivanova JI; Kirson NY; Cummings AK; Birnbaum HG; Duan R; Cao D; Hadjiyianni I
    Curr Med Res Opin; 2016; 32(4):669-80. PubMed ID: 26703951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan.
    Hadjiyianni I; Desai U; Suzuki S; Ivanova JI; Cao D; Kirson NY; Chida D; Enloe C; Birnbaum HG; Perez-Nieves M
    Diabetes Ther; 2017 Feb; 8(1):149-166. PubMed ID: 27913984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
    Kalirai S; Duan R; Liu D; Reed BL
    J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey.
    Perez-Nieves M; Ivanova JI; Hadjiyianni I; Zhao C; Cao D; Schmerold L; Kalirai S; King S; DeLozier AM; Birnbaum HG; Peyrot M
    Curr Med Res Opin; 2017 Oct; 33(10):1833-1842. PubMed ID: 28604111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
    Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: An exploratory analysis from a UK real-world sample.
    Idris I; Gulati K; Perez-Nieves M; Hadjiyianni I; Cao D; Tahbaz A; Ivanova J; Hassan SW
    Prim Care Diabetes; 2019 Apr; 13(2):106-112. PubMed ID: 30477969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients' Treatment Persistence Behavior: Real-World Data from Germany.
    Moennig E; Perez-Nieves M; Hadjiyianni I; Cao D; Ivanova J; Klask R
    Exp Clin Endocrinol Diabetes; 2018 May; 126(5):287-297. PubMed ID: 28895642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of basal insulin persistence among insulin-naïve people with type 2 diabetes: results from a multinational survey.
    Peyrot M; Perez-Nieves M; Ivanova J; Cao D; Schmerold L; Kalirai S; Hadjiyianni I
    Curr Med Res Opin; 2017 Oct; 33(10):1843-1851. PubMed ID: 28604112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
    Rashid N; McCombs JS; Schwartz E
    Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal insulin persistence in Brazilian participants with T2DM.
    Franco DR; Perez-Nieves M; Ivanova JI; Cao D; Vaz MSC
    Rev Assoc Med Bras (1992); 2019; 65(10):1254-1264. PubMed ID: 31721957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
    Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
    Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benchmarking Insulin Treatment Persistence Among Patients with Type 2 Diabetes Across Different U.S. Payer Segments.
    Wei W; Jiang J; Lou Y; Ganguli S; Matusik MS
    J Manag Care Spec Pharm; 2017 Mar; 23(3):278-290. PubMed ID: 28230445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States.
    Kalirai S; Ivanova JI; Perez-Nieves M; Stephenson JJ; Hadjiyianni I; Grabner M; Pollom RD; Geremakis C; Reed BL; Fisher L
    Diabetes Metab Syndr Obes; 2020; 13():1023-1033. PubMed ID: 32308452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.